Whitehawk Therapeutics Inc
NASDAQ:WHWKBiotechnology
+$0.06 today
- Market cap
- $184.70M
- Beta
- 0.77
- P/E (TTM)
- -2.6
- EPS (TTM)
- -$1.67
Volume 0.28M
Average 0.31M
WHWK Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Whitehawk Therapeutics IncNASDAQ: WHWK
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income growth accelerates
Q4 FY2025 net income of $23.25M (cash outflow) rose 27.2% year over year, ahead of the -67.7% change in trailing-twelve-month net income. Sequentially, it rose 31.0% from the prior quarter. Over 3 fiscal years it compounded at -30.2% a year.
Context
- Net income amounted to 288.3% of revenue in FY2025, up 43.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$57.94M (+181.3%) for the fiscal year ending Dec 2026, a step up from the -67.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$23.25M+31.0% QoQ
- Last fiscal yearDec 2025
- -$20.6M-67.7% YoY
- LTMDec 2025
- -$20.6M-67.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (20.6M) USD
- Year-over-year change
- +67.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (20.6M) | +67.7% |
| FY2024 | 2024-12-31 | (63.69M) | +3.2% |
| FY2023 | 2023-12-31 | (65.77M) | -8.7% |
| FY2022 | 2022-12-31 | (60.51M) | +45.0% |
| FY2021 | 2021-12-31 | (110.09M) | — |
Net Income vs competitors
How WHWK compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -67.7% is the lowest of 9, against a peer median of +14.0%.
- Net income amounts to 288.3% of revenue for WHWK, versus a peer median of 339.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.13M USD | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $113.22M USD | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $40.23M USD | +45.6% | +34.5% | — | |
| LTM Mar 2026 | CA$35.52M CAD | +12.8% | +16.7% | — | |
| LTM Mar 2026 | $34.98M USD | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $33.51M USD | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $24.17M USD | -3.2% | -31.5% | 339.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M USD | -67.7% | -30.2% | 288.3% |
| Peer median (excluding WHWK) | — | +14.0% | +1.1% | 339.3% | |
Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (110.09M) | (60.51M) | (65.77M) | (63.69M) | (20.6M) |
| Depreciation & Amortization | 105K | 159K | 169K | 193K | 79K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.11M | 9.64M | 11.95M | 10.84M | 9.87M |
| Change in Working Capital | 3.96M | (5.04M) | (3.27M) | 3.72M | 1.93M |
| Accounts Receivables | 14.15M | (1.86M) | (3.63M) | (415K) | (1M) |
| Inventory | 0 | (1.86M) | (3.27M) | 1.12M | 170K |
| Accounts Payables | 0 | 0 | 0 | 0 | 3.92M |
| Other Working Capital | (10.19M) | (1.32M) | 3.62M | 3.02M | (1.16M) |
| Other Non-Cash Items | 81.5M | 6.11M | (2.75M) | (10.61M) | (78.77M) |
| Operating Cash Flow | (22.42M) | (49.64M) | (59.66M) | (59.55M) | (97.43M) |
| Capital Expenditures | (46K) | (444K) | (3.97M) | (1.65M) | (552K) |
| Acquisitions (Net) | 25.2M | 0 | 0 | 0 | 101.29M |
| Purchases of Investments | 0 | (145.19M) | (64.44M) | (36.48M) | (148.69M) |
| Sales of Investments | 0 | 12.75M | 151.62M | 63.34M | 59.85M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 25.15M | (132.89M) | 83.21M | 25.2M | 11.89M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 155M | 72.5M | 0 | 130K | 100M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (4.41M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.78M) | 120K | 326K | (16K) | (5.63M) |
| Financing Cash Flow | 141.8M | 72.62M | 326K | 130K | 94.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 64K |
| Net Change in Cash | 144.53M | (109.91M) | 23.87M | (34.22M) | 8.9M |
| Free Cash Flow | (22.47M) | (50.08M) | (63.64M) | (61.2M) | (97.99M) |
Whitehawk Therapeutics Inc
NASDAQ:WHWK
Intrinsic Alpha fair value
Locked
Current Price
$3.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.